Recently, however, therapeutic editing of a breast cancer oncogene (LCN2, encoding Lipocalin-2) has been achieved by using an innovative vehicle (tNLG: targeted-NanoLipoGel) for delivery of CRISPR-Cas9 plasmids in TNBC cells. The gene discussed is LCN2; the disease is breast carcinoma.